Navan (NAVN) IPO deck
MapLight Therapeutics is a clinical-stage biopharma developing treatments for neuropsychiatric and CNS disorders, led by its Phase 2 candidate ML-007C-MA for schizophrenia and Alzheimer’s psychosis.
MapLight Therapeutics is a clinical-stage biopharma developing treatments for neuropsychiatric and CNS disorders, led by its Phase 2 candidate ML-007C-MA for schizophrenia and Alzheimer’s psychosis.
%20IPO%20deck){kind=link}